Marc Bourlière Selected Research

Antigens

1/2017	Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
12/2006	Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Marc Bourlière Research Topics

Disease

39	Infections 02/2024 - 05/2002
31	Chronic Hepatitis C 01/2023 - 05/2002
31	Fibrosis (Cirrhosis) 10/2022 - 12/2006
14	Hepatitis C 02/2024 - 10/2006
12	Liver Cirrhosis (Hepatic Cirrhosis) 06/2024 - 07/2005
12	Hepatocellular Carcinoma (Hepatoma) 01/2022 - 08/2007
10	Neoplasms (Cancer) 01/2023 - 04/2016
8	Liver Diseases (Liver Disease) 10/2022 - 12/2006
5	Chronic Hepatitis B 02/2022 - 10/2006
4	Liver Neoplasms (Liver Cancer) 08/2020 - 04/2016
4	Anemia 01/2016 - 04/2009
3	Portal Hypertension 05/2024 - 04/2015
3	Autoimmune Hepatitis 01/2022 - 04/2006
3	Coinfection 01/2019 - 01/2006
3	Neutropenia 01/2018 - 01/2013
2	Hepatitis B 06/2024 - 12/2008
2	Viremia 06/2024 - 01/2018
2	Hypertension (High Blood Pressure) 02/2022 - 01/2018
2	Chronic Renal Insufficiency 01/2022 - 01/2018
2	Disease Progression 01/2021 - 11/2019
2	Inflammation (Inflammations) 04/2015 - 12/2006
2	Virus Diseases (Viral Diseases) 02/2015 - 02/2006
2	Pruritus (Itching) 02/2012 - 04/2009
2	Exanthema (Rash) 02/2012 - 04/2009
2	Chronic Hepatitis (Chronic Active Hepatitis) 08/2007 - 04/2006
1	Hepatitis D 06/2024
1	Cardiovascular Diseases (Cardiovascular Disease) 01/2023
1	Ascites 10/2022
1	Dyslipidemias (Dyslipidemia) 02/2022
1	Cholestasis 01/2022
1	End Stage Liver Disease 01/2022
1	Cholangitis 01/2022
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2022
1	Focal Nodular Hyperplasia 01/2022
1	Chronic Kidney Failure (Chronic Renal Failure) 01/2022
1	Iron Overload 01/2022
1	HIV Infections (HIV Infection) 11/2021
1	Esophageal and Gastric Varices (Esophageal Varices) 01/2019
1	Thrombocytopenia 4 01/2018
1	Leukopenia 01/2018
1	Diabetes Mellitus 01/2018

Drug/Important Bio-Agent (IBA)

34	Ribavirin (Virazole)FDA LinkGeneric 01/2017 - 05/2002
32	Antiviral Agents (Antivirals)IBA 02/2024 - 02/2006
24	InterferonsIBA 11/2018 - 05/2002
11	RNA (Ribonucleic Acid)IBA 06/2024 - 01/2006
10	Protease Inhibitors (Protease Inhibitor)IBA 01/2017 - 06/2011
9	N- (3- amino- 1- (cyclobutylmethyl)- 2,3- dioxopropyl)- 3- (2- ((((1,1- dimethylethyl)amino)carbonyl)amino)- 3,3- dimethyl- 1- oxobutyl)- 6,6- dimethyl- 3- azabicyclo(3.1.0)hexan- 2- carboxamideIBA 03/2016 - 02/2012
9	telaprevirIBA 01/2016 - 04/2009
7	SofosbuvirIBA 01/2022 - 01/2015
7	faldaprevirIBA 05/2016 - 06/2011
5	daclatasvirIBA 01/2018 - 02/2014
4	Hepatitis B Surface Antigens (HBsAg)FDA Link 06/2024 - 01/2017
4	alpha-Fetoproteins (alpha-Fetoprotein)IBA 08/2020 - 06/2017
4	peginterferon alfa-2a (Pegasys)FDA Link 01/2017 - 10/2006
4	deleobuvirIBA 02/2015 - 08/2013
3	Coffee FDA Link 06/2022 - 01/2019
3	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 02/2012
3	ledipasvirIBA 01/2017 - 01/2015
3	sofosbuvir drug combination ledipasvirIBA 01/2017 - 04/2015
3	peginterferon alfa-2b (Pegintron)FDA Link 01/2013 - 02/2007
2	Transaminases (Aminotransferases)IBA 06/2024 - 01/2018
2	DNA (Deoxyribonucleic Acid)IBA 01/2023 - 01/2017
2	AutoantibodiesIBA 01/2022 - 01/2022
2	BilirubinIBA 08/2020 - 01/2018
2	Aspartate Aminotransferases (Aspartate Transaminase)IBA 11/2019 - 01/2009
2	TabletsIBA 01/2018 - 01/2015
2	elbasvirIBA 01/2018 - 01/2017
2	grazoprevirIBA 01/2018 - 01/2017
2	sofosbuvir velpatasvir voxilaprevir drug combinationIBA 01/2018 - 01/2017
2	velpatasvirIBA 01/2017 - 12/2015
2	AntigensIBA 01/2017 - 12/2006
2	Hemoglobins (Hemoglobin)IBA 01/2017 - 01/2013
2	N- (8- aminohexyl)- 5- iodonaphthalene- 1- sulfonamide (W8)IBA 03/2016 - 01/2016
2	Inosine TriphosphataseIBA 01/2016 - 01/2015
2	NucleosidesIBA 01/2015 - 02/2014
2	asunaprevirIBA 02/2014 - 01/2013
2	InterleukinsIBA 02/2014 - 01/2012
2	Erythropoietin FDA Link 09/2013 - 08/2007
2	Biomarkers (Surrogate Marker)IBA 03/2007 - 07/2005
1	hemoglobin DIBA 06/2024
1	CannabinoidsIBA 10/2022
1	4-(3-chlorophenylsulfanyl)piperidineIBA 10/2022
1	Ferritins (Ferritin)IBA 01/2022
1	Contrast MediaIBA 01/2022
1	AlbuminsIBA 08/2020
1	Ethiodized Oil (Ethiodol)FDA Link 11/2019
1	Sorafenib (BAY 43-9006)FDA Link 11/2019
1	glecaprevir and pibrentasvirIBA 01/2018
1	omega-Chloroacetophenone (Mace)IBA 01/2018
1	Serum AlbuminIBA 01/2018
1	glecaprevirIBA 01/2018
1	pibrentasvirIBA 01/2018

Therapy/Procedure

33	Therapeutics 02/2024 - 05/2002
4	Retreatment 01/2018 - 04/2007
3	Liver Transplantation 10/2022 - 01/2021
3	Duration of Therapy 11/2019 - 05/2002
2	Transplantation 01/2020 - 01/2018
1	Surgical Portasystemic Shunt (Portosystemic Shunt) 05/2024
1	Transjugular Intrahepatic Portasystemic Shunt 05/2024
1	Renal Dialysis (Hemodialysis) 01/2018